Study of QL1706, bevacizumab, and chemo infusion for liver cancer with portal vein clot
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three treatments for people with advanced liver cancer that has spread into the main portal vein. The goal is to see if this therapy can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced liver cancer (HCC) with a tumor clot in the main portal vein or its first branches (Vp3 or Vp4).
- You should not have received any prior systemic therapy for liver cancer, like targeted drugs or immunotherapy.
- Your liver tumor must be at least 7 centimeters across, and you should have at least one measurable tumor that hasn't been treated with radiation.
- You must be in fairly good health, with a performance status of 0 or 1 (able to carry out daily activities).
- Your liver and kidney function must meet certain blood test requirements, and your cancer must be at a stage where you're expected to live at least 12 more weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (bevacizumab and adebrelimab) plus a special procedure called TACE-HAIC to treat advanced liver cancer that cannot be surgically removed. The goal is to see if this combination is safe and effective as a first-line treatment.
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
This study tests QL1706 together with bevacizumab and/or chemotherapy as an initial (first) treatment for advanced liver cancer. It may help shrink tumors or control the disease when surgery or local treatments aren’t suitable.
This trial combines two immunotherapy drugs with a targeted therapy, radiation, and a liver-directed chemotherapy infusion for liver cancer that has spread to the portal vein (the main blood vessel to the liver). The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
Hear when a new Hepatecellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.